Introduction {#s1}
============

Since the last version of the WHO classification of tumors of the CNS was published in 2007, knowledge on genetic alterations and biological features of medulloblastoma has rapidly increased by (epi)genome- and transcriptome-wide studies. In particular, RNA expression studies and DNA methylation profiling have led to the identification of "biological" variants of medulloblastoma defined by predominant signalling pathways and DNA methylation patterns associated to their cellular origin \[[@b24]\]. These molecular subgroups overlap with histological features in some cases but are discordant in others. While the WHO classification 2007 relied on histological features only, the challenge of its update in 2016 was to integrate meaningful genetic/biological information to enable a more precise classification of medulloblastoma without disrupting the continuity of the classification system. Continuity is especially needed for (1) longitudinal comparisons of outcome data of clinical studies, (2) the comparison of associated research data, and (3) a reliable basis for epidemiological information on the incidence of the disease entities.

This challenge was elegantly resolved by the introduction of the integrated diagnosis concept in the WHO classification 2016 \[[@b17]\]. Most CNS tumor entities are still classified on only histopathological features, but in medulloblastoma, the definition of disease entities requires an integration of additional molecular information. This approach improves the definition of the medulloblastoma entities, reduces the interobserver variability in diagnostics, and allows a better selection of patients for treatment stratification as well as improved prediction of treatment response and prognosis. By this approach, the traditional histological diagnosis (e.g., "classic medulloblastoma") and the histological grade of malignancy ("WHO grade IV") are combined with defined molecular genetic/biological features (e.g., "WNT activation"). In daily diagnostic practice, the histological part of the diagnosis can be made in the same short time frame as before, the molecular diagnostic part requires additional tests which might need more time for analysis, but finally, an integrated diagnosis e.g., "classic medulloblastoma, WNT activated, WHO grade IV" can be signed out, now precisely describing a well-defined disease entity.

Some limitations for the integration of molecular characteristics come from a technical aspect. The methods employed for proper classification of medulloblastomas have to be (1) available or accessible in most neuropathological units worldwide and (2) certifiable as diagnostic test systems. In the WHO classification 2016 no recommendation for the use of specific test systems or methods is given, but care was taken that the implementation of molecular markers for classification is possible in daily diagnostic practise in most laboratories.

WHO classification of medulloblastomas -- histologically and genetically defined {#s2}
================================================================================

Although the five histological entities of medulloblastomas according to the 2007 classification could be validated as prognostic and useful in the stratification of patients for risk-adapted treatment in clinical studies, in particular in young children, the histological subtyping had several limitations. For example, interobserver variability in the assessment of certain histological features caused problems, e.g., the differentiation of "true" desmoplastic medulloblastoma variants vs. cases with desmoplastic (reactive) changes due to superficial growth, or the differentiation between large cell and anaplastic medulloblastoma variants in cases showing both cytological components. The histological subtype was often found related to certain genetic/biological features of the tumors but considered to be not as distinctive as a definition by mRNA expression or DNA methylation signatures. To improve the precision of medulloblastoma diagnostics, the histological typing is now combined with genetic information to allow for an informative diagnosis. In the histological part, only one adaptation was made in the WHO classification 2016: the large cell and anaplastic medulloblastomas are now jointly diagnosed as large cell/anaplastic (LCA) medulloblastomas because it was felt difficult to differentiate these rare entities that often show a mixed cellular composition. This term had also been used in the 2000 WHO classification before. The definitions of the *histologically defined* medulloblastoma variants did otherwise not change significantly compared to the WHO classification 2007 ([Table 1](#Table1){ref-type="table"}).

Regarding the *genetically defined* component of the diagnosis, four main entities were newly defined ([Table 1](#Table1){ref-type="table"}) \[[@b4]\].

One entity is "medulloblastoma, WNT-activated". These tumors cannot be identified on hematoxylin-eosin (H & E)-stained sections alone; most of them have classic morphology but immunohistochemically show nuclear accumulation of β-catenin protein as surrogate biomarker for WNT activation caused by *CTNNB1* activating mutations or -- rarely -- mutations in *APC* or other genes encoding components of the WNT signaling pathway \[[@b6], [@b11], [@b12]\]. The precise identification of these tumors is important because of their excellent prognosis in the pediatric age (\< 16 years) and inclusion of patients into ongoing therapeutic trials aiming to prove that reduction of treatment intensity is possible in these patients (e.g., the European SIOP PNET5 medulloblastoma trial). In the setting of such clinical trials, it is widely recommended to use two independent methods for reliable identification of these patients such as immunohistochemistry for β-catenin and sequencing of *CTNNB1* exon 3 or alternative methods (Nanostring RNA profiling, methylation classifiers) \[[@b7]\].

Tumors showing mRNA expression and DNA methylation profiles suggesting activation of sonic hedgehog (SHH) signaling are considered to represent two very different disease entities, depending on the *TP53*genetic status \[[@b13], [@b26]\]. Therefore, two genetically defined entities are "medulloblastoma, SHH-activated and *TP53*-mutant" and "medulloblastoma, SHH-activated and *TP53*-wildtype". The latter occur mostly in adolescents/adults and young children who have a good prognosis if adequately treated. In contrast, *TP53*-mutant SHH medulloblastomas occur in older children and have a dismal prognosis \[[@b26]\]. SHH activation is caused by mutations in *PTCH1*, *SUFU*, *SMO,* or other components of the SHH signaling pathway \[[@b20]\]. Fortunately, SHH activation can be reliably assessed by different methods including a panel of antibodies against SHH target proteins (see below) \[[@b5], [@b14]\]. On the other hand, if a SHH-activated tumor is identified, the *TP53* genetic status has to be determined for a precise classification. Proper identification of SHH activation is also important because a significant fraction of young children with SHH-activated medulloblastomas have underlying germ-line mutations of *PTCH1* or *SUFU* (Gorlin syndrome) \[[@b2]\]. These patients and their families should be offered genetic counselling. The same is true for patients suffering from *TP53*-mutant SHH medulloblastomas indicating possible *TP53* germline mutations (Li-Fraumeni syndrome) or other germline defects.

The fourth genetically defined entity represents the majority of medulloblastomas lacking either WNT or SHH pathway activation (non-WNT/non-SHH medulloblastomas). These tumors seem to lack recurrent mutations but show frequent chromosomal copy number alterations such as isochromosome 17q. They can be further subdivided with DNA methylation profiling or mRNA expression studies in "group 3" and "group 4" medulloblastomas. *MYC* amplification is frequently found in young children with group 3 tumors, and metastatic disease at diagnosis and is associated with a very dismal outcome. Group 3 and 4 variants have so far only been considered as provisional subentities because it is not absolutely clear if they represent distinct diseases or variants of a single entity.

In adult patients, only three biological medulloblastoma subgroups have been identified: WNT, SHH, and group 4 \[[@b22]\]. In contrast to children, WNT tumors could not be associated with improved survival and patients with group 4 tumors have been reported to have a dismal outcome as compared to patients with SHH and WNT tumors \[[@b25]\].

All combinations between histological and genetic parts of the medulloblastoma classification scheme are theoretically possible, but there are frequent associations. For example, most WNT-activated medulloblastomas are of classic histology (as are most non-WNT/non-SHH medulloblastomas), most SHH-activated cases with *TP53*-mutation show an anaplastic phenotype, and almost all desmoplastic/nodular medulloblastomas and those with extensive nodularity are SHH-activated \[[@b20]\]. The term "medulloblastoma, not otherwise specified (NOS)" should be restricted to cases with insufficient material for further analysis or inconclusive results of molecular testing. In summary, the concept of an integrated diagnosis is used for WHO classification of medulloblastomas and allows a precise assignment of patients for risk-adapted stratification. It also allows comparison to results of study cohorts in the past and provides a robust basis for further treatment refinement.

Histopathological assessment in neuropathological practice {#s3}
==========================================================

For proper definition of the histopathological component of the medulloblastoma diagnosis, the tumors should be assigned to one of the four entities classic, desmoplastic/nodular (DNMB), extensive nodular (MBEN) or large cell/anaplastic (LC/A) medulloblastoma ([Figure 1](#Figure1){ref-type="fig"}). One important issue is the differentiation of "true" desmoplastic/nodular medulloblastoma variants ([Figure 1](#Figure1){ref-type="fig"}C, D) vs. cases with desmoplastic (reactive) changes due to superficial growth ([Figure 1](#Figure1){ref-type="fig"}E, F), and vs. cases showing nodular appearance but no reticulin fibers ([Figure 1](#Figure1){ref-type="fig"}G, H) \[[@b18]\]. For correct identification of desmoplastic/nodular medulloblastoma both H & E staining and silver impregnation (reticulin staining) is necessary. Reticulin fibers must be present ensheating nodular areas lacking such argyrophilic fibers. A reactive desmoplastic reaction, which may occur in all types of medulloblastomas does not result in a regular nodular pattern as seen in DNMB. On the other hand, a tumor qualifies for the diagnosis of DNMB if the characteristic pattern is present in restricted areas only, even if other parts lack a desmoplastic/nodular histology. Nodular medulloblastoma entities do usually not contain neuroblastic rosettes. MBEN is regarded as being closely related to DNMB but has to contain larger islands with differentiated neurocytic cells. These should be predominant and can be illustrated by strong expression of NeuN antigen. MBEN as well as DNMB must show a SHH activation according to the revised WHO classification 2016 \[[@b20]\]; therefore, immunohistochemistry for SHH target proteins can be used for the differential diagnosis of nodular entities vs. classic medulloblastoma (see below). For the diagnosis of large cell/anaplastic medulloblastoma, a severely anaplastic ([Figure 1](#Figure1){ref-type="fig"}I) or a large cell component ([Figure 1](#Figure1){ref-type="fig"}H) or a mixture of both should be predominant (more that 50% of the tumor area). Cytological anaplasia is reflected by increased nuclear variability, frequent mitoses/apoptoses and nuclear wrapping, while the large cell cytology is characterized by cells with round larger nuclei with singular prominent nucleoli. The latter cells frequently show a dot-like immunoreactivity with antibodies against synaptophysin \[[@b21]\].

Practical approach to the assessment of the genetic component of medulloblastoma {#s4}
================================================================================

For proper identification of the four genetic entities according to the WHO classification, a combination of immunohistochemistry and genetic assays are very helpful.

The WNT-activated medulloblastomas (\~ 10% of all medulloblastoma), the two medulloblastoma entities with SHH activation (with or without *TP53*alteration, together \~ 30% of all medulloblastomas), and the non-WNT/non-SHH medulloblastomas can be securely differentiated by a set of immunohistochemical markers ([Table 2](#Table2){ref-type="table"}) ([Figure 2](#Figure2){ref-type="fig"}), namely β-Catenin, Yap1, p75NGFR (or Gab1), and Otx2. WNT medulloblastomas show nuclear accumulation of β-catenin protein in addition to Yap1 immunoreactivity in tumor nuclei and express Otx2 \[[@b4], [@b14]\]. SHH-activated medulloblastomas express specific target proteins such as p75NGFR and Gab1, share expression of nuclear Yap1 with the WNT medulloblastoma, but lack Otx2 expression. Non-WNT/non-SHH medulloblastomas finally express Otx2 but lack the other markers such as Yap1 (which is only expressed in endothelial cells in this tumor type serving as internal control ([Figure 2](#Figure2){ref-type="fig"}) and nuclear β-catenin. Recently produced batches of the Gab1 antibody do not seem to deliver reliable staining results, and we therefore recommend the use of Otx2 and p75NGFR instead.

Immunohistochemistry for p53 should be performed at least in all SHH-activated tumors, because p53 accumulation strongly indicates the SHH-activated *TP53-*altered medulloblastoma entity \[[@b26]\]. Most of these tumors show cytological anaplasia, at least focally. In SHH-activated tumors, *TP53*should be sequenced with validated methods in certified laboratories to clearly differentiate between the SHH-activated medulloblastoma entities with and without *TP53*alteration because of important consequences for treatment decisions and possible germ line alterations. It is a matter of debate if the sequencing of SHH-activated medulloblastomas can be restricted to tumors which show p53 accumulation (\> 5% of nuclei), and/or signs of cytological anaplasia or if all SHH-activated medulloblastoma should be sequenced. Tabori et al. \[[@b23]\] found a 100% sensitivity of p53 accumulation to predict *TP53*mutations in medulloblastomas. The age distribution of SHH-activated, *TP53*-altered cases shows a peak in the school-age so that SHH-MB tumors in these children should be carefully analyzed \[[@b13]\].

Most of the non-WNT/non-SHH medulloblastomas can be further subdivided in the provisional "group 3" and "group 4" variants by expression or methylation profiling. Although it has been suggested in the literature that group 3 and 4 tumors can be distinguished by immunohistochemical stainings \[[@b19]\], this could not be confirmed \[[@b1], [@b10]\], and to date no robust simple technologies (e.g., immunohistochemical methods) are available for their precise distinction. Even with array-based analytical methods, there is a "grey zone" between groups 3 and 4, with tumors switching groups if different algorithms for data analysis are employed. In pediatric patients, "group 3" non-WNT/non-SHH medulloblastomas contain standard-risk medulloblastomas (not behaving differently from "group 4" patients) as well as *MYC*-amplified tumors showing mostly a very poor prognosis. *MYC* amplification is considered an important prognostic biomarker within the non-WNT/non-SHH medulloblastomas \[[@b21]\] but not as a diagnostic marker defining an own entity.

In Europe, multinational multicenter trials for the treatment of children with medulloblastoma, such as the standard risk medulloblastoma SIOP-PNET5 medulloblastoma trial, have set a framework for the establishment of national neuropathological reference centers for central review and classification of medulloblastomas in the last years. In these centers, validated methods have been established and harmonized. However, all immunohistochemical tests as well as genetic analyses should be validated in each diagnostic neuropathological unit to allow secure assignment of medulloblastoma patients according to the revised WHO classification 2016.

MYC and MYCN FISH analyses {#s5}
==========================

*MYC* and *MYCN* amplification ([Figure 3](#Figure3){ref-type="fig"}) have been described as important negative prognostic factors in pediatric medulloblastoma \[[@b15]\], and the negative impact of *MYC* amplification could be confirmed in adults \[[@b9]\]. Several methods can be used to detect gene amplifications including interphase FISH, CGH/SNP/molecular inversion profiling (MIP)/methylation arrays. iFISH analysis is considered the "gold-standard" for analysis of the *MYC* and *MYCN* copy number status in medulloblastomas in neuropathological practice. It allows a copy number estimation for specific genes on a single-cell level, detection of intratumoral heterogeneity, and requires only few tissue amounts of either FFPE tissue. As failure rates of iFISH on FFPE tissue in up to 15% of the cases are common, touch preparations of unfixed or frozen tumor tissue are recommended. In the majority of amplified cases, the vast majority of tumor cells harbor the amplification. Yet, a small number of tumors may also show only focal/patchy amplification. In the SIOP PNET5 study the cut-off for amplification is ≥ 5%, (in 200 non-overlapping nuclei) yet, it needs to be clarified whether patients with focal/patchy amplification have the same poor prognosis as patients with widespread amplification.

Differential diagnostic considerations in neuropathological practice {#s6}
====================================================================

In general, medulloblastomas of the different entities express neural markers such as Map2 and CD56, and also frequently the synaptic protein synaptophysin. Other undifferentiated tumors of the cerebellum should be excluded. In young children, AT/RT, ETMR, and CPC should be considered in particular. Immunohistochemistry with antibodies against Ini1/Smarcb1, Lin28, EMA, and cytokeratin is very helpful in this regards since medulloblastomas lack loss of Ini1 and do not show expression of the other antigens. Anaplastic ependymomas may be detected by staining with antibodies against EMA and GFAP. Undifferentiated gliomas can be identified by staining with antibodies against GFAP and Olig2. Diffuse midline gliomas frequently harbor a H3K27 mutation and can be detected with a specific antibody. Sarcomas are identified by silver impregnation methods (reticulin staining).

In adults, metastatic disease of melanomas or small cell/neuroendocrine carcinomas should be considered and immunohistochemistry for cytokeratins and melanotic antigens (HMB-45/MelanA) may be appropriate.

In summary, widely accessible and robust methods are available to allow a precise diagnosis of medulloblastoma entities according to the revised WHO classification of brain tumors 2016, and for differential diagnostic purposes. Novel technologies including genome-wide methylation arrays or sequencing techniques are now used in many neuropathological units for research projects. However, these methods have to be thoroughly validated and qualified for certification before they might be used as tools for clinical diagnostics in the future.
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Table 1.Medulloblastoma is classified by an integrative diagnosis including a histologically as well as genetically defined compound.*Medulloblastoma, histologically defined*   Medulloblastoma, classic   Medulloblastoma, desmoplastic/nodular   Medulloblastoma with extensive nodularity   Medulloblastoma, large cell/anaplastic*Medulloblastoma, genetically defined*   Medulloblastoma, WNT-activated   Medulloblastoma, SHH-activated, TP53 mutated   Medulloblastoma, SHH-activated, TP53 wild-type   Medulloblastoma, non-WNT/non-SHH   Medulloblastoma, group 3 \*   Medulloblastoma, group 4 \*Medulloblastoma, NOS\*\*[^1]

Table 2.Antibodies and FISH probes recommended for the analysis of medulloblastomas.AntigenAntibody/CloneSupplierMedulloblastoma subtype(s)Referenceβ-cateninMouse MAb/C14Cell Marque, Rocklin, CA, USAWNT (nuclear accumulation)Ellison et al. 2011 \[[@b5]\]P75-NGFRMouse MAb/NGFR5Thermo, Runcorn, UKSHHKüchler et al. 2011 \[[@b14]\]Gab1Rabbit polyclonal Cat \# 06-79Merck-Millipore, Darmstadt, GermanySHHEllison et al. 2011 \[[@b5]\]Yap1Rabbit Mab/D8H1XCell Signaling, Danvers, MA, USAWNT and SHHEllison et al. 2011 \[[@b5]\]Otx2Mouse MAb/1H12C4B5Thermo Fisher, Rockford, IL, USAWNT and Non-WNTnon-SHHDe Haas et al. 2006 \[[@b2]\]NeuNMouse MAb/A60Merck-Millipore, Darmstadt, GermanyMBEN-SHHGiangaspero et al. 2016 \[[@b7]\]P53Mouse MAb/DO-7Dako, Hamburg, GermanySHH-T53 altered\
WNT with TP53 alterationTabori et al. 2010 \[[@b23]\]\
Zhukova et al. 2013 \[[@b26]\]GeneFISH ProbesSupplierMB subtype(s)MYCVysis LSI MYC/CEP8Abbott, Wiesbaden, GermanyNon-WNT/non-SHHMYC (8q24)/SE 8Kreatech/Leica, Wetzlar, GermanyMYCNVysis LSI N-MYC (2p24)/CEP 2AbbottSHH-p53 altered Non-WNT/non-SHHMYCN (2p24)/AFF3 (2q11)Kreatech

![Histologically defined entities of medulloblastoma. A: Classic medulloblastoma with (B) strong NeuN expression in preexisting granule cells and weaker expression in tumor cells (NeuN); C: desmoplastic/nodular medulloblastoma with (D) reticulin fibers in internodular areas (reticulin stain); E: classic medulloblastoma without pale nodular areas but with (F) desmoplastic reaction due to leptomeningeal invasion (reticulin stain); G: classic medulloblastoma with pale nodules but (H) without desmoplasia (reticulin stain); I, J: large/cell anaplastic medulloblastoma with (I) severely anaplastic nuclei with nuclear moulding/wrapping and frequent mitotic and apoptotic figures; J: large round cells with prominent nucleoli.](clinneuropathol-35-344-01){#Figure1}

![Characteristic immunophenotype of WNT-activated (upper panel), SHH-activated (middle panel) and non-WNT/non-SHH medulloblastomas (lower panel).](clinneuropathol-35-344-02){#Figure2}

![FISH showing representative tumors with (A) *MYC* amplification (*MYC* = red, CEP8 = green) and (B) *NMYC* amplification (*MYCN* = green, CEP2 = red).](clinneuropathol-35-344-03){#Figure3}

[^1]: \*Provisional entity; \*\*NOS (not otherwise specified) should only be used when no appropriate material is available for classification.
